A pilot study of axi-cel in primary and secondary CNS lymphomas 

Lakshmi Nayak, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a pilot study on the safety and efficacy of axicabtagene ciloleucel (axi-cel) in patients with primary and secondary central nervous system (CNS) lymphomas. The study found that the safety profile, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), was comparable to that in patients without CNS involvement. Additionally, response rates were high and durable. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.